COMPASS Pathways plc
COMPASS Pathways plc (CMPS): 4 pipeline candidates · 4 upcoming catalysts · ~30 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
30.0 months
D/E 0.63 · 0% dilution
Lead: Phase 3
4 candidates
4 upcoming, next in ~12d
N/A
A transparent, data-derived signal for COMPASS Pathways plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6B
Cash
$466.4M
Quarterly Burn
$47.9M
Runway
30.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| COMP360 | Phase 3 |
| comp360 psilocybin | Phase 2/Phase 3 |
| COMP360 psilocybin treatment | Phase 3 |
| Psilocybin | Phase 2 |
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
193
Total value held
$511.9M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 12,161,496 | $67.3M |
| rtw investments, lp | 10,632,390 | $58.8M |
| marshall wace, llp | 4,038,335 | $22.3M |
| tang capital management llc | 4,002,200 | $22.1M |
| caption management, llc | 3,610,230 | $20.0M |
| susquehanna international group, llp | 3,387,888 | $18.7M |
| ark investment management llc | 3,301,050 | $18.3M |
| millennium management llc | 3,138,522 | $17.4M |
| two sigma investments, lp | 2,583,499 | $14.3M |
| dafna capital management llc | 2,418,882 | $13.4M |
Showing top 10 of 193 institutional holders of COMPASS Pathways plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in COMPASS Pathways plc's pipeline?
COMPASS Pathways plc (CMPS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is COMPASS Pathways plc's lead drug candidate?
COMPASS Pathways plc's most advanced tracked candidate is COMP360 (Phase 3) for PTSD - Post Traumatic Stress Disorder.
What is COMPASS Pathways plc's next catalyst?
COMPASS Pathways plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder" — expected June 30, 2026.
What is COMPASS Pathways plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, COMPASS Pathways plc has approximately 30.0 months of cash runway.
What is COMPASS Pathways plc's market capitalization?
COMPASS Pathways plc's market capitalization is approximately $1.6B.
Get the full picture on COMPASS Pathways plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.